National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 27756 [2020-09979]
Download as PDF
<![CDATA[
27756
Federal Register / Vol. 85, No. 91 / Monday, May 11, 2020 / Notices
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, RFP 75N93019R00024,
‘‘Chemistry Center for Combating AntibioticResistant Bacteria (CC4CARB)’’.
Date: June 9–10, 2020.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, 3G13, Rockville,
MD 20892 (Telephone Conference Call).
Contact Person: Brenda Lange-Gustafson,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, 3G13,
Rockville, MD 20852, 240–669–5047,
bgustafson@niaid.nih.gov,
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 5, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09977 Filed 5–8–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
VerDate Sep<11>2014
17:05 May 08, 2020
Jkt 250001
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, HIV/AIDS Clinical Trial
Units.
Date: June 5–8, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Cynthia Louise De La
Fuente, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room
3G31, Rockville, MD 20852, 240–669–2740,
delafuentecl@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 5, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09979 Filed 5–8–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, email or call the SAMHSA
Reports Clearance Officer at
carlos.graham@samhsa.hhs.gov or (240)
276–0361.
Proposed Project: Program Evaluation
for Prevention Contract (PEPC)—
Strategic Prevention Framework for
Prescription Drugs (SPF–Rx) Evaluation
(OMB No. 0930–0377)—Revision
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA) Center for Behavioral Health
Statistics and Quality (CBHSQ) aims to
complete a cross-site evaluation of
SAMHSA’s Strategic Prevention
Framework for Prescription Drugs (SPF–
Rx). SPF–Rx is designed to address
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
nonmedical use of prescription drugs as
well as opioid overdoses by raising
awareness about the dangers of sharing
medications and by working with
pharmaceutical and medical
communities on the risks of
overprescribing. The SPF–Rx program
aims to promote collaboration between
states/tribes and pharmaceutical and
medical communities to understand the
risks of overprescribing to youth ages
12–17 and adults 18 years of age and
older. The program also aims to enhance
capacity for, and access to, Prescription
Drug Monitoring Program (PDMP) data
for prevention purposes. This request
for data collection includes a revision
from previously approved OMB
instruments.
The SPF–Rx program’s indicators of
success are reductions in opioid
overdoses, reductions in prescription
drug misuse, and improved use of
PDMP data. Data collected through the
tools described in this statement will be
used for the national cross-site
evaluation of SAMHSA’s SPF–Rx
program. This package covers continued
data collection through 2023. The PEPC
team will systematically collect and
maintain an Annual Implementation
Instrument (AII) and Grantee and
Community Level Outcomes data
modules submitted by SPF–Rx grantees
through the online Data Management
System (DMS).
SAMHSA is requesting approval for
data collection for the SPF–Rx cross-site
evaluation with the following
instruments:
• Annual Implementation Instrument
(AII)—The AII is a survey instrument
collected yearly to monitor state, tribal
entity, and community-level
performance, and to evaluate the
effectiveness of the SPF–Rx program.
This tool is completed by grantees and
subrecipient community project
directors, and provides process data
related to funding use and effectiveness,
organizational capacity, collaboration
with community partners, data
infrastructure, planned intervention
targets, intervention implementation,
evaluation, contextual factors, training
and technical assistance (T/TA) needs,
and sustainability.
• Grantee-and Community-Level
Outcomes Modules—These modules
collect data on key SPF–Rx program
outcomes, including opioid prescribing
patterns and provider use of PDMP.
Grantees will provide outcomes data at
the grantee level for their state, tribal
area, or jurisdiction, as well as at the
community level for each of their
subrecipient communities.
• Grantee-Level Interview—This
qualitative interview will be
E:\FR\FM\11MYN1.SGM
11MYN1
]]>Agencies
[Federal Register Volume 85, Number 91 (Monday, May 11, 2020)]
[Notices]
[Page 27756]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09979]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel, HIV/AIDS Clinical Trial Units.
Date: June 5-8, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Cynthia Louise De La Fuente, Ph.D., Scientific
Review Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20852, 240-669-2740, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: May 5, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-09979 Filed 5-8-20; 8:45 am]
BILLING CODE 4140-01-P
